A team of scientists at A*STAR's Institute of Molecular and Cell Biology say they've identified a particular biomarker which can be used to identify how patients will likely respond to EGFR inhibitors. They noted that cancer cells with elevated levels of PRL-3 are more rapidly destroyed by EGFR inhibitors, making them prime candidates for therapy. Release